Abstract：
BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury.
UNASSIGNED: Ibogaine requires careful patient screening and monitoring because of significant safety issues. There is potential for cardiotoxicity (prolonged QT interval); without rigorous screening, fatal arrhythmias may occur. However, preliminary research suggests that co-administration of ibogaine with magnesium may mitigate cardiotoxicity. Additionally, ibogaine may have dangerous interactions with opiates, so patients who receive ibogaine treatment for opioid use disorder must withdraw from long-acting opioids. Other potential concerning effects of ibogaine include rare incidences of mania or psychosis. Anticipated transient effects during ibogaine treatment can include ataxia, tremors, and gastrointestinal symptoms.
UNASSIGNED: Robust effects after a single treatment with ibogaine have been reported. In open-label and randomized controlled trials (RCTs), ibogaine reduces heroin and opioid cravings by upwards of 50%, up to 24 weeks after the treatment. An observational study of 30 Special Operations Forces veterans with mild traumatic brain injury reported that 86% were in remission from post-traumatic stress disorder, 83% from depression, and 83% from anxiety, one month after a single-dose ibogaine treatment.
CONCLUSIONS: Although there are several observational and open-label studies, there is only a single double-blind, placebo-controlled RCT on ibogaine. More RCTs with large sample sizes must be conducted to support ibogaine\'s safety and efficacy.
CONCLUSIONS: Given the promising preliminary findings, ibogaine could potentially fill a much-needed gap in treatments for challenging conditions, including opioid dependence. Ibogaine\'s remarkable effects in traditionally treatment-resistant, combat-exposed individuals hints at its potential in broader populations with physical and psychological trauma.
UNASSIGNED: Ibogaine requires careful patient screening and monitoring because of significant safety issues. There is potential for cardiotoxicity (prolonged QT interval); without rigorous screening, fatal arrhythmias may occur. However, preliminary research suggests that co-administration of ibogaine with magnesium may mitigate cardiotoxicity. Additionally, ibogaine may have dangerous interactions with opiates, so patients who receive ibogaine treatment for opioid use disorder must withdraw from long-acting opioids. Other potential concerning effects of ibogaine include rare incidences of mania or psychosis. Anticipated transient effects during ibogaine treatment can include ataxia, tremors, and gastrointestinal symptoms.
UNASSIGNED: Robust effects after a single treatment with ibogaine have been reported. In open-label and randomized controlled trials (RCTs), ibogaine reduces heroin and opioid cravings by upwards of 50%, up to 24 weeks after the treatment. An observational study of 30 Special Operations Forces veterans with mild traumatic brain injury reported that 86% were in remission from post-traumatic stress disorder, 83% from depression, and 83% from anxiety, one month after a single-dose ibogaine treatment.
CONCLUSIONS: Although there are several observational and open-label studies, there is only a single double-blind, placebo-controlled RCT on ibogaine. More RCTs with large sample sizes must be conducted to support ibogaine\'s safety and efficacy.
CONCLUSIONS: Given the promising preliminary findings, ibogaine could potentially fill a much-needed gap in treatments for challenging conditions, including opioid dependence. Ibogaine\'s remarkable effects in traditionally treatment-resistant, combat-exposed individuals hints at its potential in broader populations with physical and psychological trauma.
摘要：
背景：伊博加因是一种植物衍生的生物碱，已在西非中部的通行仪式和精神仪式中使用了数千年。在西方,它主要用于和研究其抗成瘾特性，最近用于其他神经精神病学适应症，包括创伤后应激障碍,抑郁症,焦虑,和创伤性脑损伤。
■Ibogaine需要仔细的患者筛查和监测，因为严重的安全问题。有潜在的心脏毒性（延长QT间期）；没有严格的筛查，可能发生致命的心律失常。然而,初步研究表明,伊博加因与镁联合给药可以减轻心脏毒性.此外,伊博加因可能与阿片类药物有危险的相互作用，因此，接受伊博加因阿片类药物使用障碍治疗的患者必须退出长效阿片类药物。伊博加因的其他潜在影响包括罕见的躁狂或精神病发生率。伊波加因治疗期间预期的短暂影响可能包括共济失调，震颤,和胃肠道症状。
■已经报道了用伊博加因单次治疗后的稳健效果。在开放标签和随机对照试验(RCT)中，伊博加因将海洛因和阿片类药物的渴望减少了50%以上，治疗后24周。一项对30名特种作战部队退伍军人轻度创伤性脑损伤的观察研究报告称，86％的人从创伤后应激障碍中缓解，83%来自抑郁症，83%来自焦虑，单剂量伊波加因治疗一个月后。
结论：尽管有一些观察性和开放性研究，只有一个双盲，伊博加因的安慰剂对照RCT。必须进行更多样本量大的随机对照试验，以支持伊博加因的安全性和有效性。
结论：鉴于有希望的初步发现，伊博加因可能会填补一个急需的空白，在治疗具有挑战性的条件，包括阿片类药物依赖。伊博加因在传统治疗抗性中的显着效果，战斗暴露的个体暗示了其在更广泛的身体和心理创伤人群中的潜力。
■Ibogaine需要仔细的患者筛查和监测，因为严重的安全问题。有潜在的心脏毒性（延长QT间期）；没有严格的筛查，可能发生致命的心律失常。然而,初步研究表明,伊博加因与镁联合给药可以减轻心脏毒性.此外,伊博加因可能与阿片类药物有危险的相互作用，因此，接受伊博加因阿片类药物使用障碍治疗的患者必须退出长效阿片类药物。伊博加因的其他潜在影响包括罕见的躁狂或精神病发生率。伊波加因治疗期间预期的短暂影响可能包括共济失调，震颤,和胃肠道症状。
■已经报道了用伊博加因单次治疗后的稳健效果。在开放标签和随机对照试验(RCT)中，伊博加因将海洛因和阿片类药物的渴望减少了50%以上，治疗后24周。一项对30名特种作战部队退伍军人轻度创伤性脑损伤的观察研究报告称，86％的人从创伤后应激障碍中缓解，83%来自抑郁症，83%来自焦虑，单剂量伊波加因治疗一个月后。
结论：尽管有一些观察性和开放性研究，只有一个双盲，伊博加因的安慰剂对照RCT。必须进行更多样本量大的随机对照试验，以支持伊博加因的安全性和有效性。
结论：鉴于有希望的初步发现，伊博加因可能会填补一个急需的空白，在治疗具有挑战性的条件，包括阿片类药物依赖。伊博加因在传统治疗抗性中的显着效果，战斗暴露的个体暗示了其在更广泛的身体和心理创伤人群中的潜力。
